IDEAYA Biosciences, Inc.
IDYA
$19.13
$0.552.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 78.48% | -- | -- | -- | -2.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 78.48% | -- | -- | -- | -2.49% |
| Cost of Revenue | 261.58% | 69.59% | 86.90% | 53.65% | 56.88% |
| Gross Profit | -282.18% | -122.70% | -112.74% | -114.25% | -68.42% |
| SG&A Expenses | 54.97% | 23.88% | 46.91% | 30.35% | 22.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 229.71% | 60.94% | 79.09% | 49.35% | 50.46% |
| Operating Income | -243.87% | -99.53% | -98.50% | -94.14% | -58.52% |
| Income Before Tax | -283.78% | -88.85% | -88.97% | -67.39% | -40.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -283.78% | -88.85% | -88.97% | -67.39% | -40.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -283.78% | -88.85% | -88.97% | -67.39% | -40.30% |
| EBIT | -243.87% | -99.53% | -98.50% | -94.14% | -58.52% |
| EBITDA | -247.72% | -101.65% | -100.39% | -96.18% | -59.51% |
| EPS Basic | -186.70% | -31.49% | -36.33% | -7.82% | -3.50% |
| Normalized Basic EPS | -152.05% | -31.49% | -36.35% | -7.79% | -34.83% |
| EPS Diluted | -186.70% | -31.49% | -36.33% | -7.82% | -3.50% |
| Normalized Diluted EPS | -152.05% | -31.49% | -36.35% | -7.79% | -34.83% |
| Average Basic Shares Outstanding | 33.86% | 43.65% | 38.60% | 55.28% | 35.56% |
| Average Diluted Shares Outstanding | 33.86% | 43.65% | 38.60% | 55.28% | 35.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
